AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9010701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 1488756 — intervention group
Group type: EXPERIMENTAL
Intervention: Postremission therapy without prednisolone (PSL)
Number of subjects: 30
Study 1488756 — intervention group
Group type: COMPARATOR
Intervention: Postremission therapy with prednisolone (PSL)
Number of subjects: 30
Study 2880467 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 21
Study 2880467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29703714 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized, exclusively email-based prompts
Number of subjects: 38
Study 29703714 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized knowledge broker providing support through phone- and email-based check-ins
Number of subjects: 38
Study 28106552 — intervention group
Group type: EXPERIMENTAL
Intervention: Kirtan Kriya meditation (KK)
Number of subjects: 60
Study 28106552 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening (ML)
Number of subjects: 60
Study 25592742 — intervention group
Group type: EXPERIMENTAL
Intervention: Souvenaid™ (125 ml/day)
Number of subjects: 26
Study 25592742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 23935162 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded-independent central review (BICR)
Number of subjects: 722
Study 21931077 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined home health education (HHE) plus trained general practitioner (GP)
Number of subjects: 1341
Study 21931077 — intervention group
Group type: EXPERIMENTAL
Intervention: Home health education (HHE) only
Number of subjects: 1341
Study 21931077 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained GP only
Number of subjects: 1341
Study 21931077 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 1341
Study 19145932 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with type 2 diabetes (HbA1c < 7.5%)
Number of subjects: 58
Study 19145932 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with type 2 diabetes (HbA1c ≥ 7.5%)
Number of subjects: 58
Study 19145932 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 58
Study 16357116 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 25969 0.5 mg kg(‐1)
Number of subjects: 30
Study 16357116 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 25969 4.0 mg kg(‐1)
Number of subjects: 30
Study 16357116 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 25969 (various doses)
Number of subjects: 30
Study 16357116 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 25969 (2-4 mg kg(‐1))
Number of subjects: 30
Study 12813331 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose unfractionated heparin (UFH) 5,000 U every 8 hours
Number of subjects: 119
Study 12813331 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 119
Study 10540135 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal occult blood screening
Number of subjects: 0
Study 10540135 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-screened)
Number of subjects: 0
Study 10540135 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage A tumours
Number of subjects: 0
Study 10540135 — intervention group
Group type: EXPERIMENTAL
Intervention: Well or moderately differentiated tumours
Number of subjects: 0
Study 8941507 — intervention group
Group type: EXPERIMENTAL
Intervention: Coca chewing (15 g)
Number of subjects: 12
Study 8941507 — intervention group
Group type: COMPARATOR
Intervention: Control (sugar-free chewing gum)
Number of subjects: 12
Study 1685100 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of vecuronium
Number of subjects: 40
Study 1685100 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg of vecuronium
Number of subjects: 40
Study 1685100 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg of vecuronium
Number of subjects: 40
Study 1685100 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg of vecuronium
Number of subjects: 40
Study 1685100 — intervention group
Group type: COMPARATOR
Intervention: Anesthetized state (baseline)
Number of subjects: 40
Study 6127039 — intervention group
Group type: EXPERIMENTAL
Intervention: D-2343 (0.21-6.3 micrograms kg-1 min-1)
Number of subjects: 8
Study 6127039 — intervention group
Group type: EXPERIMENTAL
Intervention: QH 25 (0.25, 0.75, and 2.25 mg orally)
Number of subjects: 8
Study 6127039 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (0.07-2.1 micrograms kg-1 min-1)
Number of subjects: 8
Study 6127039 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (2, 6, and 18 mg orally)
Number of subjects: 8
Study 30796338 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise and resistance training (aerobic exercise thrice weekly and resistance training twice weekly for 12 weeks)
Number of subjects: 47
Study 30796338 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise and resistance training
Number of subjects: 47
Study 27718533 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-component structured manualized group intervention (MGI)
Number of subjects: 170
Study 27718533 — intervention group
Group type: COMPARATOR
Intervention: Single-component group intervention (SGI)
Number of subjects: 170
Study 25759565 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 200 mg
Number of subjects: 23
Study 25759565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 23
Study 25759565 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration of Udenafil and Dapoxetine
Number of subjects: 23
Study 24529669 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (20% of ED95 × kg)
Number of subjects: 80
Study 24529669 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study 20828895 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone filter
Number of subjects: 30
Study 20828895 — intervention group
Group type: COMPARATOR
Intervention: Bone fragment (rongeur)
Number of subjects: 30
Study 18579368 — intervention group
Group type: EXPERIMENTAL
Intervention: BPPV with volume targeting
Number of subjects: 12
Study 18579368 — intervention group
Group type: COMPARATOR
Intervention: BPPV with usual ventilator settings
Number of subjects: 12
Study 17159457 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine monotherapy, 300 or 600 mg/day
Number of subjects: 542
Study 17159457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study 15019892 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy at the time of hospital discharge
Number of subjects: 0
Study 11260155 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (SM) 50 microg, twice daily for 1 week
Number of subjects: 16
Study 11260155 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (SM)
Number of subjects: 16
Study 11260155 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 16
Study 9731049 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m2 (8 weekly infusions) - Arm A
Number of subjects: 54
Study 9731049 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 500 mg/m2 (1 infusion followed by 7 weekly infusions) - Arm B
Number of subjects: 54
Study 7495064 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression ultrasonography (CUS), Doppler ultrasound (DUS), and clinical score assessment
Number of subjects: 100
Study 7495064 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal CUS, absence of venous reflux in both common femoral and popliteal vein, and low clinical score
Number of subjects: 100
Study 7495064 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal venous reflux in the isolated common femoral vein
Number of subjects: 100
Study 7495064 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoplethysmography (PPG) determination of venous refilling time
Number of subjects: 100
Study 2658535 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 6
Study 2658535 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet
Number of subjects: 6
Study 90602 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) stimulation
Number of subjects: 10
Study 90602 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg)
Number of subjects: 10
Study 90602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31957246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator hyperinflation
Number of subjects: 48
Study 31957246 — intervention group
Group type: COMPARATOR
Intervention: Manual hyperinflation
Number of subjects: 48
Study 31828516 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheeled Walker (WW) available
Number of subjects: 17
Study 31828516 — intervention group
Group type: COMPARATOR
Intervention: No Wheeled Walker (WW) available
Number of subjects: 17
Study 30935633 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported frailty (≥ 1 symptom)
Number of subjects: 4996
Study 30935633 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefrail men (1 to 2 symptoms)
Number of subjects: 4996
Study 30935633 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail men (≥ 3 symptoms)
Number of subjects: 4996
Study 30935633 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefrail women (1 to 2 symptoms)
Number of subjects: 4996
Study 30935633 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail women (≥ 3 symptoms)
Number of subjects: 4996
Study 30935633 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported slow walk time and decreased physical activity
Number of subjects: 4996
Study 28797049 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (BICA) (0.3 g/kg)
Number of subjects: 18
Study 28797049 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 g NaCl)
Number of subjects: 18
Study 28797049 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (BICA)
Number of subjects: 18
Study 25475947 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular stapler technique
Number of subjects: 478
Study 25475947 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn technique
Number of subjects: 478
Study 25109453 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological-working memory training for four weeks
Number of subjects: 19
Study 25109453 — intervention group
Group type: COMPARATOR
Intervention: Normal classroom activities (Control)
Number of subjects: 19
Study 23080477 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia
Number of subjects: 136
Study 23080477 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study 19149890 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous sulphate (80 mg/day of elemental iron) for one month
Number of subjects: 140
Study 19149890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 17897105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 26
Study 17897105 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 26
Study 15128198 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelengths of 637, 656, 683 nm
Number of subjects: 26
Study 15128198 — intervention group
Group type: COMPARATOR
Intervention: Wavelengths of 785 nm
Number of subjects: 26
Study 12688516 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplements (two capsules per day for 4 weeks)
Number of subjects: 0
Study 12688516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two capsules per day for 4 weeks)
Number of subjects: 0
Study 10428158 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-day regimen of low-dose combined oral contraceptive (60 microg gestodene and 15 microg ethinyl estradiol)
Number of subjects: 58
Study 10428158 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-day regimen of low-dose combined oral contraceptive (60 microg gestodene and 15 microg ethinyl estradiol)
Number of subjects: 58
Study 8672330 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoxygenation with a good face mask seal (gravity alone)
Number of subjects: 16
Study 8672330 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoxygenation with a face mask held adjacent to the face
Number of subjects: 16
Study 2654865 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment (higher initial doses: >= 125 mg of cortisone or >= 100 mg of hydrocortisone)
Number of subjects: 1286
Study 2654865 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 1286
Study 1240871 — intervention group
Group type: EXPERIMENTAL
Intervention: Armadillo lepromin
Number of subjects: 112
Study 1240871 — intervention group
Group type: COMPARATOR
Intervention: Human lepromin
Number of subjects: 112
Study 31833102 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) in-home intervention
Number of subjects: 58
Study 31833102 — intervention group
Group type: COMPARATOR
Intervention: Nurse (RN) telephone management
Number of subjects: 58
Study 31618097 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual speech
Number of subjects: 84
Study 31618097 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual onset-offset cue
Number of subjects: 84
Study 31618097 — intervention group
Group type: COMPARATOR
Intervention: Auditory-only condition
Number of subjects: 84
Study 31618097 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual signal that only cued the onset and offset of the auditory syllable
Number of subjects: 84
Study 28619043 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TENS) plus conventional clinical care
Number of subjects: 208
Study 28619043 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical care
Number of subjects: 208
Study 25757070 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 65
Study 25757070 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 65
Study 24034663 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg/d, titrated to 10-20 mg/d)
Number of subjects: 641
Study 24034663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641
Study 19705272 — intervention group
Group type: EXPERIMENTAL
Intervention: Erotic female images
Number of subjects: 0
Study 19705272 — intervention group
Group type: COMPARATOR
Intervention: Clad female images
Number of subjects: 0
Study 19705272 — intervention group
Group type: COMPARATOR
Intervention: Pleasantly arousing images (e.g., skydiving)
Number of subjects: 0
Study 19705272 — intervention group
Group type: COMPARATOR
Intervention: Unpleasantly arousing images (e.g., an aimed gun)
Number of subjects: 0
Study 17574685 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of previous episodes
Number of subjects: 110
Study 17574685 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of depression
Number of subjects: 110
Study 17574685 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 110
Study 17574685 — intervention group
Group type: EXPERIMENTAL
Intervention: Social dysfunctioning
Number of subjects: 110
Study 17574685 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical functioning
Number of subjects: 110
Study 17574685 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level
Number of subjects: 110
Study 17574685 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of the longest prior episode
Number of subjects: 110
Study 17574685 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping potential
Number of subjects: 110
Study 17040302 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 128
Study 17040302 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 128
Study 15211412 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ring block with levobupivacaine
Number of subjects: 30
Study 15211412 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (2 microg/kg) and paracetamol (30 mg/kg)
Number of subjects: 30
Study 12082399 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA detection using polymerase chain reaction with E6/E7 and L1 primer sets
Number of subjects: 17
Study 12082399 — intervention group
Group type: EXPERIMENTAL
Intervention: Southern blot analysis
Number of subjects: 17
Study 12082399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloning and sequencing of HPV E6/E7 products
Number of subjects: 17
Study 12082399 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of HPV sequences from cervical swab and breast cancer
Number of subjects: 17
Study 9333933 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor)
Number of subjects: 2569
Study 9333933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2569
Study 8002621 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly injection of Romurutide (3 times per week for 3 weeks)
Number of subjects: 22
Study 8002621 — intervention group
Group type: COMPARATOR
Intervention: Five times per week injection (5 times per week for 2 weeks)
Number of subjects: 22
Study 8002621 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly injection of Romurutide
Number of subjects: 22
Study 2661880 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate Ringer dextrose (AR-D)
Number of subjects: 20
Study 2661880 — intervention group
Group type: COMPARATOR
Intervention: Lactate Ringer dextrose (LR-D)
Number of subjects: 20
Study 31864098 — intervention group
Group type: EXPERIMENTAL
Intervention: scIFN β‐1a tiw
Number of subjects: 517
Study 31864098 — intervention group
Group type: EXPERIMENTAL
Intervention: scIFN β‐1a qw
Number of subjects: 517
Study 31421060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pythagorean Self‐Awareness Intervention (PSAI) + personalized Mediterranean low‐calorie diet
Number of subjects: 49
Study 31421060 — intervention group
Group type: COMPARATOR
Intervention: Personalized Mediterranean low‐calorie diet
Number of subjects: 49
Study 28112681 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil (PO)
Number of subjects: 14
Study 28112681 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (VCL)
Number of subjects: 14
Study 26520928 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation plus tracing group
Number of subjects: 200
Study 26520928 — intervention group
Group type: COMPARATOR
Intervention: Invitation only group
Number of subjects: 200
Study 23746949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol
Number of subjects: 0
Study 23746949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21975200 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon β‐1a
Number of subjects: 0
Study 21975200 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1-year MRI lesion activity and relapses
Number of subjects: 0
Study 21975200 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year MRI lesion activity and relapses
Number of subjects: 0
Study 19792848 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP + ABBM
Number of subjects: 30
Study 19792848 — intervention group
Group type: COMPARATOR
Intervention: ABBM alone
Number of subjects: 30
Study 16822115 — intervention group
Group type: EXPERIMENTAL
Intervention: ST with CM for submitting negative urine toxicology screens
Number of subjects: 131
Study 16822115 — intervention group
Group type: EXPERIMENTAL
Intervention: ST with CM for completing goal-related activities
Number of subjects: 131
Study 16822115 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST)
Number of subjects: 131
Study 16822115 — intervention group
Group type: EXPERIMENTAL
Intervention: Longest duration of abstinence achieved during treatment
Number of subjects: 131
Study 12580650 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-PRO beverage (355 ml; approximately 0.8 g carbohydrate (CHO).kg(-1) body wt and approximately 0.2 g protein.kg(-1) body wt)
Number of subjects: 8
Study 12580650 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-PRO beverage
Number of subjects: 8
Study 11030507 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot function test (FBS, LS, TB, DP)
Number of subjects: 20
Study 9049582 — intervention group
Group type: EXPERIMENTAL
Intervention: YM17E 150 mg twice daily (b.d.)
Number of subjects: 24
Study 9049582 — intervention group
Group type: EXPERIMENTAL
Intervention: YM17E 300 mg twice daily (b.d.)
Number of subjects: 24
Study 9049582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7819790 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (Havrix, SKF) - 1 injection at day 0, 1 at D15, booster at 6 months
Number of subjects: 108
Study 7819790 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine - 1 injection at day 0
Number of subjects: 108
Study 7819790 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hepatitis A and yellow fever vaccines
Number of subjects: 108
Study 3308977 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 36
Study 3308977 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine + Desipramine
Number of subjects: 36
Study 3308977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3308977 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine alone
Number of subjects: 36
Study 30208343 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week stepped collaborative care intervention (cognitive behavioral therapy, CBT)
Number of subjects: 150
Study 30208343 — intervention group
Group type: COMPARATOR
Intervention: Attention control arm of technology-delivered health education
Number of subjects: 150
Study 27771036 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation education
Number of subjects: 19
Study 27771036 — intervention group
Group type: COMPARATOR
Intervention: Didactic education
Number of subjects: 19
Study 26156512 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with protein supplement (n = 18)
Number of subjects: 61
Study 26156512 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with placebo supplement (n = 13)
Number of subjects: 61
Study 26156512 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group (n = 10)
Number of subjects: 61